-
Infective endocarditis (IE) continues to be a serious illness with high morbidity and mortality despite modern therapies.
-
-
On 15 May the FDA Center for Biologics Evaluation and Research/Office of Blood Research and Review (CBER/OBRR) granted market clearance to the OraQuick in-home HIV-1/2 antibody test based on the recommendation of the Blood Products Advisory Committee.
-
The U.S. Food and Drug Administration (FDA) recently issued an alert on the potential risk of non-convulsive status epilepticus associated with the use of cefepime, a broad spectrum fourth generation cephalosporin.
-
FoodNet is an active surveillance program that collects data on 9 laboratory-confirmed pathogens from 10 sites in the United States: 7 states (Connecticut, Georgia, Maryland, Minnesota, New Mexico, Oregon, and Tennessee) and certain counties in California, Colorado, and New York.
-
In this issue: Lorcaserin for weight loss; statins and fatigue; treatment-resistant gonorrhea; hydrocodone classification changes; USPSTF recommendations; and FDA actions.
-
A total of 1745 infants from 17 sites in Brazil (70.1%), South Africa (27.4%), Argentina (1.6%) and the United States (0.8%) born to women with a peripartum diagnosis of HIV type I infection were randomized within 48 hours of birth to receive one of three six-week postpartum antiretroviral regimens.
-
This ProMED-mail alert describes the case of a young Rhode Island resident who traveled to Cambodia and Viet Nam, where she was hospitalized with spinal cord compression in December 2011.
-
The medical community appears to be deeply divided over a federal recommendation that would push the health system toward mandatory flu shot policies for health care workers.
-
After considerable controversy that included strong objections by the nation's leading occupational health agency, a federal vaccine committee has approved a recommendation that health care facilities strongly consider mandatory flu immunization of workers if voluntary efforts fail to achieve high vaccination rates.
